(Boursier.com) — Mauna Kea rises 2.5% to 0.39 euros this Friday. Over the whole of 2023, the group’s total turnover increased by +42% to €10.5 million, driven by the strong growth in volumes of the PPU activity in the United States and the substantial contribution license sales. The Group’s 2023 operating profit improves significantly to 1.2 ME (-9.1 ME in 2022), reflecting the positive impact of the Group’s strategic partnership with the Tasly JV.
The net result stands at -3.7 ME (-11.2 ME in 2022).
Cash and cash equivalents amounted to €8 million as of December 31, 2023, an increase of €4.8 million compared to December 31, 2022, notably thanks to the capital increase reserved for Telix Pharmaceuticals.
In the 1st quarter of 2024, the PPU activity, which represents 50% of sales in the United States, remained on the same favorable usage trends observed in 2023, with volumes up 47% year-on-year. other.
Perspectives displayed
In 2024, Mauna Kea Technologies intends to confirm its growth trajectory both through the sale of systems, probes and procedures but also by establishing new strategic partnerships.
The Group has also defined financial objectives for the year, in particular:
– growth of more than 20% in turnover excluding licensing revenues, driven by the increase in volumes in the United States;
– the doubling of production of Cellvizio systems to meet demand in different markets and support the ramp-up of the JV in China and the launch of the activity relating to food intolerances;
– the reduction in operational losses supported by business growth and continued cost reduction efforts;
– strengthening the financial structure.
Portzamparc insists on the financial visibility until Q1 2025 that the group has. The new guidance, which involves the reduction of losses and growth of more than 20% excluding licenses this year, pushes the analyst to review the cursor from 0.91 to 1 euro on the file.
©2024 Boursier.com